Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
ENTELLUS MEDICAL INC (ENTL) Create: Alert

All | News | Filings
Date FiledTypeDescription
02/28/2018 8-K Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Fa...
Docs: "Amended and Restated Certificate of Incorporation of Entellus (filed herewith)",
"Amended and Restated Bylaws of Entellus (filed herewith)"
02/26/2018 8-K Submission of Matters to a Vote of Security Holders
01/04/2018 8-K Quarterly results
12/07/2017 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : December 7, 2017 ENTELLUS MEDICAL, INC. Delaware 001-36814 20-4627978 3600 Holly Lane North, Suite 40 Plymouth, Minnesota 55447 463-1595 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☒ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to R...",
"Agreement and Plan of Merger, by and among Stryker Corporation, Explorer Merger Sub Corp. and Entellus Medical, Inc. (filed herewith)",
"Form of Voting Agreement, by and between Stryker Corporation and the applicable stockholder of Entellus Medical, Inc. (filed herewith)",
"Contact: Lynn Pieper Lewis 415-937-5402 [email protected] Entellus Medical Announces Definitive Agreement to be Acquired by Stryker Corporation for a Purchase Price of $24.00 Per Share in Cash"
11/01/2017 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 1, 2017 ENTELLUS MEDICAL, INC. Delaware 001-36814 20-4627978 3600 Holly Lane North, Suite 40 Plymouth, Minnesota 55447 463-1595 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to R...",
"ENTELLUS MEDICAL ANNOUNCES THIRD QUARTER 2017 FINANCIAL RESULTS"
09/25/2017 8-K Quarterly results
09/25/2017 8-K/A Quarterly results
08/08/2017 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Investor Presentation Slides to be used by Entellus Medical, Inc. (furnished herewith)"
08/03/2017 8-K Quarterly results
Docs: "ENTELLUS MEDICAL ANNOUNCES SECOND QUARTER 2017 FINANCIAL RESULTS PLYMOUTH, MN. - Entellus Medical, Inc. , a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis, nasal airway obstruction and persistent Eustachian tube dysfunction, today reported its financial results for the quarter ended June 30, 2017. Recent Highlights and Accomplishments"
07/14/2017 8-K Form 8-K - Current report:
07/07/2017 8-K Form 8-K - Current report
06/14/2017 8-K Form 8-K - Current report
05/03/2017 8-K Form 8-K - Current report
04/12/2017 8-K Form 8-K - Current report
04/06/2017 8-K Form 8-K - Current report
02/21/2017 8-K Form 8-K - Current report
01/31/2017 8-K Form 8-K - Current report
01/25/2017 8-K Form 8-K - Current report
01/05/2017 8-K Form 8-K - Current report
11/03/2016 8-K Form 8-K - Current report
08/03/2016 8-K Form 8-K - Current report
06/29/2016 8-K Form 8-K - Current report
06/27/2016 8-K Form 8-K - Current report
06/15/2016 8-K Form 8-K - Current report
05/23/2016 8-K Form 8-K - Current report
05/10/2016 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Investor Presentation Slides to be used by Entellus Medical, Inc. (furnished herewith)"
05/04/2016 8-K Quarterly results
Docs: "ENTELLUS MEDICAL ANNOUNCES FIRST QUARTER 2016 FINANCIAL RESULTS PLYMOUTH, MN. - Entellus Medical, Inc. , a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, today reported its financial results for the quarter ended March 31, 2016. Recent Highlights and Accomplishments • Revenue of $16.9 million in the first quarter of 2016, an increase of 25% year-over-year • Pediatric uptake in the first quarter reflects positive physician reception and adoption • Achieved balanced revenue growth across ENT offices and ORs, with In-Office revenue representing 54% of U.S. product revenue in the first quarter “We are off to a strong start in 2016 with continu..."
02/24/2016 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "ENTELLUS MEDICAL ANNOUNCES FOURTH QUARTER AND FULL YEAR 2015 FINANCIAL RESULTS AND ISSUES 2016 FINANCIAL OUTLOOK PLYMOUTH, MN. - Entellus Medical, Inc. , a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, today reported its financial results for the quarter and year ended December 31, 2015. Recent Highlights and Accomplishments"
02/22/2016 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/11/2016 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/09/2015 8-K Quarterly results
Docs: "ENTELLUS MEDICAL ANNOUNCES THIRD QUARTER 2015 FINANCIAL RESULTS INCREASES FULL YEAR REVENUE GUIDANCE PLYMOUTH, MN. - Entellus Medical, Inc. , a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, today reported its financial results for the quarter ended September 30, 2015. Recent Highlights and Accomplishments"
08/14/2015 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Fiagon NA Distributor Agreement, effective 10 August 2015, by and between Fiagon NA Corporation and Entellus Medical, Inc"
08/06/2015 8-K Quarterly results
Docs: "ENTELLUS MEDICAL ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS PLYMOUTH, MN. - Entellus Medical, Inc. , a medical technology company focused on the design, development and commercialization of products for the minimally invasive treatment of chronic and recurrent sinusitis patients in the physician office setting or operating room, today reported its financial results for the quarter ended June 30, 2015. Recent Highlights and Accomplishments"
07/09/2015 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "ENTELLUS MEDICAL APPOINTS JOHN BAKEWELL TO ITS BOARD OF DIRECTORS PLYMOUTH, MN, July 9, 2015 — Entellus Medical, Inc. , a medical technology company focused on designing, developing and commercializing products for the minimally invasive treatment of chronic and recurrent sinusitis patients, today announced that John Bakewell, Chief Financial Officer of Lantheus Holdings, Inc. , has been appointed to its Board of Directors and will be serving on the audit committee, effective July 7, 2015. Mr. Bakewell is an accomplished senior executive with more than twenty years of financial and administrative leadership experience concentrated in the medical device and healthcare provider sectors. Over the course of his career, Mr. Bakewell has held the role of Chief Financial Officer at seven companie..."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy